866-997-4948(US-Canada Toll Free)

Thalassemia - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 141 Pages

Thalassemia - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 8, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thalassemia - Overview 6
Thalassemia - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Thalassemia - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Thalassemia - Companies Involved in Therapeutics Development 23
Acceleron Pharma Inc 23
Agios Pharmaceuticals Inc 23
Alnylam Pharmaceuticals Inc 24
bluebird bio Inc 24
Cadila Healthcare Ltd 25
Calimmune Inc 25
CRISPR Therapeutics 26
Editas Medicine Inc 26
Errant Gene Therapeutics LLC 27
Gamida Cell Ltd 27
Gilead Sciences Inc 28
Incyte Corp 28
Ionis Pharmaceuticals Inc 29
IRBM Science Park SpA 29
Kiadis Pharma NV 30
La Jolla Pharmaceutical Company 30
Merck & Co Inc 31
Protagonist Therapeutics Inc 31
Sangamo Therapeutics Inc 32
Thalassemia - Drug Profiles 33
(decitabine + tetrahydrouridine) - Drug Profile 33
ACY-957 - Drug Profile 34
AG-348 - Drug Profile 37
ALN-TMP - Drug Profile 42
ambrisentan - Drug Profile 44
ATIR-201 - Drug Profile 47
BB-305 - Drug Profile 48
benserazide - Drug Profile 57
CAL-H - Drug Profile 59
CordIn - Drug Profile 60
Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile 61
Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile 62
Gene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia - Drug Profile 63
GSK-2696277 - Drug Profile 64
IMR-687 - Drug Profile 65
IONISTMPRSS-6LRx - Drug Profile 66
LJPC-401 - Drug Profile 67
luspatercept - Drug Profile 69
M-009 - Drug Profile 78
M-012 - Drug Profile 79
NiCord - Drug Profile 81
PEG-EPO - Drug Profile 85
PHBB-101 - Drug Profile 86
PTG-300 - Drug Profile 87
RCY-1497 - Drug Profile 88
RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile 89
ruxolitinib phosphate - Drug Profile 90
SCD-101 - Drug Profile 105
sirolimus - Drug Profile 106
Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile 107
Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile 108
sotatercept - Drug Profile 109
ST-400 - Drug Profile 114
Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile 116
Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile 117
Stem Cell Therapy to Activate Hemoglobin Beta for Beta-Thalassemia - Drug Profile 119
Thalagen - Drug Profile 120
Thalassemia - Dormant Projects 121
Thalassemia - Product Development Milestones 122
Featured News & Press Releases 122
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 137
Disclaimer 138

List of Tables
Number of Products under Development for Thalassemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Thalassemia - Pipeline by Acceleron Pharma Inc, H2 2017
Thalassemia - Pipeline by Agios Pharmaceuticals Inc, H2 2017
Thalassemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
Thalassemia - Pipeline by bluebird bio Inc, H2 2017
Thalassemia - Pipeline by Cadila Healthcare Ltd, H2 2017
Thalassemia - Pipeline by Calimmune Inc, H2 2017
Thalassemia - Pipeline by CRISPR Therapeutics, H2 2017
Thalassemia - Pipeline by Editas Medicine Inc, H2 2017
Thalassemia - Pipeline by Errant Gene Therapeutics LLC, H2 2017
Thalassemia - Pipeline by Gamida Cell Ltd, H2 2017
Thalassemia - Pipeline by Gilead Sciences Inc, H2 2017
Thalassemia - Pipeline by Incyte Corp, H2 2017
Thalassemia - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Thalassemia - Pipeline by IRBM Science Park SpA, H2 2017
Thalassemia - Pipeline by Kiadis Pharma NV, H2 2017
Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H2 2017
Thalassemia - Pipeline by Merck & Co Inc, H2 2017
Thalassemia - Pipeline by Protagonist Therapeutics Inc, H2 2017
Thalassemia - Pipeline by Sangamo Therapeutics Inc, H2 2017
Thalassemia - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Thalassemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *